Regeneron reported modest revenue growth in Q4 2025, supported by higher collaboration revenue, while net income declined year over year due to higher R&D spending and margin pressure.

Regeneron delivered solid financial results in Q3 2025 with slight revenue growth and robust profitability. Strong Dupixent sales and FDA approvals helped offset declines in EYLEA sales.

Regeneron Pharmaceuticals, Inc. delivered a strong second quarter in 2025, with total revenues increasing by 4% to $3.68 billion and non-GAAP EPS growing by 12% to $12.89. The company saw significant sales growth in EYLEA HD and Dupixent, achieved multiple FDA approvals for key products, and made substantial progress in its oncology and other therapeutic pipelines.

Regeneron faced a slight revenue decrease but achieved strong profitability driven by robust Dupixent sales and strategic pipeline advancements.

Regeneron reported a 10% increase in revenue for Q4 2024, reaching $3.79 billion. GAAP EPS was $8.06, and non-GAAP EPS was $12.07. The company initiated a quarterly dividend program and increased its share repurchase capacity to approximately $4.5 billion.

Regeneron reported a strong third quarter with an 11% increase in revenue to $3.72 billion. Key drivers include growth from Dupixent and Libtayo, as well as continued leadership in the retinal franchise with EYLEA HD and EYLEA. The company also highlighted advancements in its clinical pipeline, including FDA approvals for Dupixent and positive trial results for various programs.

Regeneron reported a strong second quarter in 2024, with a 12% increase in total revenue, driven by growth in key products such as EYLEA HD, Dupixent and Libtayo. The European Commission approved Dupixent as the first biologic therapy for uncontrolled COPD. The company is also advancing its clinical pipeline, with late-stage trials for Dupixent, itepekimab, fianlimab and Libtayo.

Regeneron reported first quarter 2024 financial results with a 1% decrease in total revenue to $3.145 billion. Excluding Ronapreve, revenues increased by 7%. The company saw significant growth in Dupixent and Libtayo sales, and the pipeline progressed with regulatory submissions and approvals.

Regeneron reported a 1% increase in revenue to $3.43 billion for Q4 2023. Excluding Ronapreve, revenue increased by 14%. GAAP diluted EPS was $10.19, and non-GAAP diluted EPS was $11.86. Key products like Dupixent and Libtayo saw significant sales growth. The company also submitted Dupixent sBLA for COPD and linvoseltamab BLA for multiple myeloma to the FDA.

Regeneron reported a strong third quarter in 2023, with a 15% increase in revenue to $3.36 billion. This growth was primarily driven by Dupixent and Libtayo, along with the launch of EYLEA HD. The company also highlighted pipeline advancements, including FDA priority review designations for odronextamab and Dupixent.

Regeneron reported an 11% increase in revenue to $3.16 billion for the second quarter of 2023. GAAP diluted EPS was $8.50, and non-GAAP diluted EPS was $10.24. The company progressed its pipeline, including aflibercept 8 mg, and saw a 33% increase in Dupixent global net sales.

Regeneron reported a 7% increase in first quarter 2023 revenues, reaching $3.16 billion. The company saw growth in Dupixent global sales and U.S. EYLEA sales, accompanied by progress in its clinical pipeline with multiple regulatory approvals and positive trial results. GAAP diluted EPS was $7.17, and non-GAAP diluted EPS was $10.09, including an unfavorable $0.42 impact from acquired IPR&D charge.

Regeneron reported a decrease in total revenue for Q4 2022, but experienced growth when excluding REGEN-COV and Ronapreve. Key achievements included the submission of a BLA for aflibercept 8 mg and approvals for Libtayo and Dupixent in specific indications.

Regeneron's Q3 2022 revenues decreased by 15% to $2.94 billion, but excluding REGEN-COV, revenues increased by 11%. EYLEA U.S. net sales increased by 11% to a record $1.63 billion, while Dupixent global net sales increased by 40% to $2.33 billion. The company reported GAAP diluted EPS of $11.66 and non-GAAP diluted EPS of $11.14.

Regeneron reported a 44% decrease in revenue to $2.86 billion for Q2 2022, primarily due to the absence of REGEN-COV® sales. Excluding REGEN-COV®, revenue increased by 20%. The company saw record net product sales for EYLEA, Dupixent and Libtayo. GAAP diluted EPS was $7.47, while non-GAAP diluted EPS was $9.77, including an unfavorable impact from acquired IPR&D charges.

Regeneron reported a strong first quarter in 2022, with total revenues increasing by 17% to $2.97 billion. Excluding REGEN-COV, revenues increased by 25%. GAAP diluted EPS was $8.61, and non-GAAP diluted EPS was $11.49. The company saw substantial U.S. sales growth for EYLEA and Dupixent worldwide.

Regeneron reported a strong fourth quarter with a 104% increase in revenue to $4.95 billion, driven by REGEN-COV sales and growth in EYLEA and Dupixent. GAAP diluted EPS was $19.69, and non-GAAP diluted EPS was $23.72.

Regeneron reported a strong third quarter in 2021, with total revenues increasing by 51% to $3.45 billion compared to the third quarter of 2020. GAAP diluted EPS was $14.33 and non-GAAP diluted EPS was $15.37. The company saw growth in EYLEA U.S. net sales and Dupixent global net sales.

Regeneron reported a substantial increase in revenue for Q2 2021, driven by REGEN-COV sales and strong performance from EYLEA and Dupixent. The company also highlighted advancements in its clinical pipeline, including positive Phase 3 data for Dupixent and Libtayo.

Regeneron reported a strong first quarter in 2021, with total revenues increasing by 38% to $2.53 billion. GAAP diluted EPS was $10.09, and non-GAAP diluted EPS was $9.89. The company saw significant growth in EYLEA U.S. net sales and Dupixent global net sales. Additionally, three FDA approvals were received for Libtayo and Evkeeza, and positive data was reported from Phase 3 trials with REGEN-COV.

Regeneron reported a 30% increase in revenue for Q4 2020, reaching $2.42 billion, driven by strong sales of EYLEA and Dupixent, and the introduction of REGEN-COV. GAAP diluted EPS was $10.24, and non-GAAP diluted EPS was $9.53. The company also highlighted the FDA Emergency Use Authorization for REGEN-COV and positive clinical trial data.

Regeneron reported a strong Q3 2020 with a 32% increase in revenue to $2.29 billion. GAAP diluted EPS was $7.39 and non-GAAP diluted EPS was $8.36. Key developments included positive results for REGN-COV2 in COVID-19 outpatients and FDA acceptance for priority review of Libtayo for advanced non-small cell lung cancer and basal cell carcinoma.

Regeneron reported a 24% increase in revenue to $1.95 billion for Q2 2020, driven by strong performance of key products like EYLEA and Dupixent. The company advanced its COVID-19 antibody cocktail, REGN-COV2, into late-stage clinical trials and saw FDA approval of Dupixent for children aged 6 to 11 years with moderate-to-severe atopic dermatitis. GAAP diluted EPS was $7.61, and non-GAAP diluted EPS was $7.16.

Regeneron reported a strong first quarter in 2020, with revenues increasing by 33% to $1.83 billion. The company saw growth in key products like EYLEA, Dupixent, and Libtayo, and is advancing its COVID-19 antibody cocktail treatment.

Regeneron reported a strong fourth quarter in 2019, with revenues increasing by 13% to $2.17 billion. GAAP diluted EPS was $6.93, and non-GAAP diluted EPS was $7.50. The company highlighted commercial growth, pipeline progress, and positive financial results, with a focus on driving growth with EYLEA, Dupixent, and Libtayo in 2020.